Lakeland Fire + Safety Appoints Calven Swinea as Chief Financial Officer Financial and Accounting Veteran Leading ERP Implementation and Next Phase of Company Growth HUNTSVILLE, Ala., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. ("Lakeland Fire + Safety" or "Lakeland") (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced the appointment of Calven Swinea as Chief Financial Officer, effectively immediately. Mr. Swinea was appointed Interim Chief Financial Officer, effective January 202...
Lakeland Fire + Safety's Jolly Scarpe Delivers Urgent Boot Order to Italian Government for Winter Olympic Games Full Stock Availability Enabled Delivery in Under 48 Hours to Olympic Locations HUNTSVILLE, Ala., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. ("Lakeland Fire + Safety" or "Lakeland") (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced the shipment and delivery of an urgent order through its Jolly Scarpe brand from the Italian Ministry of the Interior - Department of Publi...
Lakeland Fire + Safety Awarded Contract from UK County Fire and Rescue Services for Firefighting Gloves Multi-Year Agreement Highlights Ability to Meet Increasingly Rigorous Procurement Standards HUNTSVILLE, Ala., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. ("Lakeland Fire + Safety" or "Lakeland") (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced that its Eagle FR subsidiary has been awarded a significant multi-year contract to supply Ultimate Glow+ structural firefighting glove...
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address both lung and liver manifestations of this disease Wave plans to engage FDA on potential accelerated approval pathway for WVE-006, with regulatory feedback anticipated mid-2026 Data from the 400 mg multidose cohort of RestorAATion-2 clinical...
Lakeland Fire + Safety Secures Tender from Belgian Federal and Local Police Departments for Safety Footwear Third Award in Six-Year Tender Agreement Demonstrates Global Reach Across Industry Verticals HUNTSVILLE, Ala., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. ("Lakeland Fire + Safety" or "Lakeland") (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced it has received an order from the Belgian Federal Police and Local Police departments for certified safety footwear. Terms of th...
Lakeland Fire + Safety Issues Shareholder Letter and Provides Corporate Update HUNTSVILLE, Ala., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. ("Lakeland Fire + Safety" or "Lakeland") (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today issued a letter to shareholders from Jim Jenkins, President, Chief Executive Officer and Executive Chairman. Dear Lakeland Shareholders, Lakeland Fire + Safety’s fiscal year 2026, which ends January 31st, was underscored by both opportunities and challenges. Wh...
Lakeland Fire + Safety Achieves NFPA 1970 Certification for Ultimate Glow+ Leather Firefighting Gloves-NFPA 321 Series Milestone Marks the First NFPA 1970 Certificated Product in Lakeland Fire + Safety’s Portfolio HUNTSVILLE, Ala., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Lakeland Industries, Inc. ("Lakeland Fire + Safety" or "Lakeland") (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced that its Lakeland Ultimate Glow+ Leather Firefighting Gloves-NFPA 321 Series has officially achieved NFPA 1970:2025 c...
Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio Wave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to incretin and as post-incretin maintenance in 2026 Initial WVE-007 240 mg single-dose data reported in 2025 demonstrated improved body composition with fat l...
ARO-ALK7 Shows Promising mRNA Knockdown and Fat Reduction. ALK7 is an Activin receptor that is encoded by the ACVR1C gene and expressed in adipose tissue. ARWR reported placebo-adjusted visceral fat reduction of 14.1% from a single dose of 200mg at week 8. According to ARWR, the ARO-ALK7 program is
Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET. A live webcast of the presentation can be accessed by visiti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.